This Cnj-016 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth during the historic period can be attributed to factors such as the increasing prevalence of immunodeficiency diseases, a growing adoption of immunoglobulin therapies, an expanding geriatric population, a higher incidence of autoimmune diseases, and increased awareness among healthcare professionals.
Market growth during the forecast period can be attributed to factors such as increased healthcare spending, an aging population, a shift towards subcutaneous administration, strategic collaborations, and supportive regulatory frameworks. Major trends during this period include technological advancements, growing awareness, increased research and development activities, market expansion, and the development of tailored immunoglobulin therapies.
The growing prevalence of immunodeficiency diseases is expected to drive the growth of the cnj-016 market. Immunodeficiency diseases occur when the immune system is unable to effectively fight infections and diseases, either due to genetic factors, environmental influences, or specific medical conditions and treatments. The rising number of immunodeficiency cases is linked to these factors. CNJ-016, a vaccinia immune globulin, helps by providing passive immunity, offering protection against complications such as eczema vaccinatum, progressive vaccinia, and other vaccinia virus-related adverse events, particularly in patients with weakened immune systems. For example, in December 2024, HIV.gov reported that 39.9 million people worldwide were living with HIV in 2023. This growing prevalence of immunodeficiency diseases is thus contributing to the growth of the cnj-016 market.
The increase in smallpox vaccination is expected to boost the growth of the cnj-016 market. Smallpox vaccination provides immunity against smallpox, a contagious and potentially deadly viral disease caused by the variola virus. The rise in smallpox vaccination is driven by global health concerns about the potential reemergence of infectious diseases. CNJ-016 plays a critical role in smallpox vaccination by offering passive immunity to individuals with weakened immune systems or those at risk of complications from the vaccinia virus, which is used in the smallpox vaccine. For instance, in May 2023, the Centers for Disease Control and Prevention (CDC) reported that 1.2 million doses of the JYNNEOS vaccine had been administered, achieving about 37% first-dose coverage and 23% second-dose coverage among the at-risk population. Consequently, the rise in smallpox vaccination is a key factor driving the growth of the cnj-016 market.
The increasing emphasis on personalized medicine is expected to propel the growth of the cnj-016 market. Personalized medicine tailors treatments and therapies to an individual’s genetic makeup, environment, and lifestyle. The growth of personalized medicine is fueled by advancements in genomic technologies, increased access to big data analytics, and a growing range of targeted therapies designed for specific genetic profiles. CNJ-016 offers targeted treatment options for individuals with compromised immune systems, reducing the risk of complications from vaccinations or viral infections based on their unique medical needs and immune profiles. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Therefore, the rising focus on personalized medicine is contributing to the growth of the cnj-016 market.
The key company operating in the cnj-016 market is Emergent Biosolutions Inc.
North America was the largest region in the cnj-016 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cnj-016 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
CNJ-016 is a vaccinia immune globulin (VIG) product, a biological treatment used to manage severe complications arising from smallpox vaccination, such as eczema vaccinatum. Derived from human plasma, it is rich in antibodies against the vaccinia virus and is primarily used for patients who experience life-threatening reactions to the virus, including those with eczema or compromised immune systems.
The primary clinical indications for cnj-016 include eczema vaccinatum, progressive vaccinia, and severe generalized vaccinia. Eczema vaccinatum is a rare but severe complication that occurs in individuals with eczema (atopic dermatitis) after exposure to the vaccinia virus, often through smallpox vaccination. CNJ-016 is distributed through various channels, including direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is used by several end users, including hospitals, clinics, and home care settings.
The cnj-016 market research report is one of a series of new reports that provides cnj-016 market statistics, including cnj-016 industry global market size, regional shares, competitors with a cnj-016 market share, detailed cnj-016 market segments, market trends, and opportunities, and any further data you may need to thrive in the cnj-016 industry. This cnj-016 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the cnj-016 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cnj-016 market consists of sales of human immune globulin and Vaccinia immune globulin intravenous. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth during the historic period can be attributed to factors such as the increasing prevalence of immunodeficiency diseases, a growing adoption of immunoglobulin therapies, an expanding geriatric population, a higher incidence of autoimmune diseases, and increased awareness among healthcare professionals.
Market growth during the forecast period can be attributed to factors such as increased healthcare spending, an aging population, a shift towards subcutaneous administration, strategic collaborations, and supportive regulatory frameworks. Major trends during this period include technological advancements, growing awareness, increased research and development activities, market expansion, and the development of tailored immunoglobulin therapies.
The growing prevalence of immunodeficiency diseases is expected to drive the growth of the cnj-016 market. Immunodeficiency diseases occur when the immune system is unable to effectively fight infections and diseases, either due to genetic factors, environmental influences, or specific medical conditions and treatments. The rising number of immunodeficiency cases is linked to these factors. CNJ-016, a vaccinia immune globulin, helps by providing passive immunity, offering protection against complications such as eczema vaccinatum, progressive vaccinia, and other vaccinia virus-related adverse events, particularly in patients with weakened immune systems. For example, in December 2024, HIV.gov reported that 39.9 million people worldwide were living with HIV in 2023. This growing prevalence of immunodeficiency diseases is thus contributing to the growth of the cnj-016 market.
The increase in smallpox vaccination is expected to boost the growth of the cnj-016 market. Smallpox vaccination provides immunity against smallpox, a contagious and potentially deadly viral disease caused by the variola virus. The rise in smallpox vaccination is driven by global health concerns about the potential reemergence of infectious diseases. CNJ-016 plays a critical role in smallpox vaccination by offering passive immunity to individuals with weakened immune systems or those at risk of complications from the vaccinia virus, which is used in the smallpox vaccine. For instance, in May 2023, the Centers for Disease Control and Prevention (CDC) reported that 1.2 million doses of the JYNNEOS vaccine had been administered, achieving about 37% first-dose coverage and 23% second-dose coverage among the at-risk population. Consequently, the rise in smallpox vaccination is a key factor driving the growth of the cnj-016 market.
The increasing emphasis on personalized medicine is expected to propel the growth of the cnj-016 market. Personalized medicine tailors treatments and therapies to an individual’s genetic makeup, environment, and lifestyle. The growth of personalized medicine is fueled by advancements in genomic technologies, increased access to big data analytics, and a growing range of targeted therapies designed for specific genetic profiles. CNJ-016 offers targeted treatment options for individuals with compromised immune systems, reducing the risk of complications from vaccinations or viral infections based on their unique medical needs and immune profiles. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Therefore, the rising focus on personalized medicine is contributing to the growth of the cnj-016 market.
The key company operating in the cnj-016 market is Emergent Biosolutions Inc.
North America was the largest region in the cnj-016 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cnj-016 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
CNJ-016 is a vaccinia immune globulin (VIG) product, a biological treatment used to manage severe complications arising from smallpox vaccination, such as eczema vaccinatum. Derived from human plasma, it is rich in antibodies against the vaccinia virus and is primarily used for patients who experience life-threatening reactions to the virus, including those with eczema or compromised immune systems.
The primary clinical indications for cnj-016 include eczema vaccinatum, progressive vaccinia, and severe generalized vaccinia. Eczema vaccinatum is a rare but severe complication that occurs in individuals with eczema (atopic dermatitis) after exposure to the vaccinia virus, often through smallpox vaccination. CNJ-016 is distributed through various channels, including direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is used by several end users, including hospitals, clinics, and home care settings.
The cnj-016 market research report is one of a series of new reports that provides cnj-016 market statistics, including cnj-016 industry global market size, regional shares, competitors with a cnj-016 market share, detailed cnj-016 market segments, market trends, and opportunities, and any further data you may need to thrive in the cnj-016 industry. This cnj-016 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The countries covered in the cnj-016 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cnj-016 market consists of sales of human immune globulin and Vaccinia immune globulin intravenous. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. CNJ-016 Market Characteristics4. CNJ-016 Market Trends and Strategies5. CNJ-016 Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global CNJ-016 Pricing Analysis & Forecasts30. Global CNJ-016 Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the CNJ-016 Market32. Recent Developments in the CNJ-016 Market
3. CNJ-016 Market Biologic Drug Characteristics
6. Global CNJ-016 Growth Analysis and Strategic Analysis Framework
8. CNJ-016 Market Segmentation
9. Global CNJ-016 Epidemiology of Clinical Indications
10. CNJ-016 Market Regional and Country Analysis
11. Asia-Pacific CNJ-016 Market
12. China CNJ-016 Market
13. India CNJ-016 Market
14. Japan CNJ-016 Market
15. Australia CNJ-016 Market
16. South Korea CNJ-016 Market
17. Western Europe CNJ-016 Market
18. UK CNJ-016 Market
19. Germany CNJ-016 Market
20. France CNJ-016 Market
21. Eastern Europe CNJ-016 Market
22. North America CNJ-016 Market
23. USA CNJ-016 Market
24. Canada CNJ-016 Market
25. South America CNJ-016 Market
26. Middle East CNJ-016 Market
27. Africa CNJ-016 Market
28. CNJ-016 Market Competitive Landscape and Company Profiles
29. Global CNJ-016 Market Pipeline Analysis
33. CNJ-016 Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Cnj-016 Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cnj-016 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cnj-016? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cnj-016 market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Eczema Vaccinatum; Progressive Vaccinia; Severe Generalized Vaccinia2) by Distribution Channel: Direct Sales; Pharmaceutical Wholesalers; Online Pharmacies; Retail Pharmacies
3) by End User: Hospitals; Clinics; Homecare
Key Companies Mentioned: Emergent Biosolutions Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Emergent Biosolutions Inc.
